Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. The company also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Pioneering Therapies | Cabaletta Bio leads in autoimmune CAR-T development, focusing on myositis and scleroderma treatments with potential for durable drug-free remissions |
Market Dynamics | Explore CABA's position in the competitive autoimmune treatment landscape, balancing first-mover advantage against intensifying industry rivalry |
Financial Tightrope | Delve into CABA's financial challenges, including limited market cap and cash burn, contrasted with its strong liquidity and undervalued status |
Future Prospects | Analyst targets range from $6 to $50, reflecting diverse views on CABA's potential in the promising yet uncertain autoimmune CAR-T market |
Metrics to compare | CABA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCABAPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.0x | −2.4x | −0.5x | |
PEG Ratio | 0.02 | −0.02 | 0.00 | |
Price/Book | 1.1x | 1.2x | 2.6x | |
Price / LTM Sales | - | 11.6x | 3.3x | |
Upside (Analyst Target) | - | 207.7% | 45.4% | |
Fair Value Upside | Unlock | 33.8% | 7.7% | Unlock |